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ARTICLE
A microengineered vascularized bleeding model
that integrates the principal components of
hemostasis
Yumiko Sakurai1,2, Elaissa T. Hardy1,2, Byungwook Ahn1,2, Reginald Tran1,2, Meredith E. Fay1,2,
Jordan C. Ciciliano 3, Robert G. Mannino1,2, David R. Myers1,2, Yongzhi Qiu1,2, Marcus A. Carden2,
W. Hunter Baldwin2, Shannon L. Meeks2, Gary E. Gilbert4, Shawn M. Jobe5 & Wilbur A. Lam1,2
Hemostasis encompasses an ensemble of interactions among platelets, coagulation factors,
blood cells, endothelium, and hemodynamic forces, but current assays assess only isolated
aspects of this complex process. Accordingly, here we develop a comprehensive in vitro
mechanical injury bleeding model comprising an “endothelialized” microﬂuidic system cou-
pled with a microengineered pneumatic valve that induces a vascular “injury”. With perfusion
of whole blood, hemostatic plug formation is visualized and “in vitro bleeding time” is
measured. We investigate the interaction of different components of hemostasis, gaining
insight into several unresolved hematologic issues. Speciﬁcally, we visualize and quantita-
tively demonstrate: the effect of anti-platelet agent on clot contraction and hemostatic plug
formation, that von Willebrand factor is essential for hemostasis at high shear, that hemo-
philia A blood confers unstable hemostatic plug formation and altered ﬁbrin architecture, and
the importance of endothelial phosphatidylserine in hemostasis. These results establish the
versatility and clinical utility of our microﬂuidic bleeding model.
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Following vascular injury, the hemostatic response is acti-vated and a complex, yet carefully balanced, ensemble ofbiological, biochemical, and biophysical interactions is
initiated1, 2. Under the hemodynamic shear conditions of the
circulation, platelets initially adhere to the vascular wound site via
von Willebrand factor (vWF) and collagen binding. Adherent
platelets release biochemical agonists that induce platelet aggre-
gation and result in the formation of a hemostatic plug, thereby
triggering the coagulation cascade to initiate ﬁbrin polymeriza-
tion and establish a more stable clot3. While in vitro assays have
enabled signiﬁcant advances in our understanding of this com-
plicated process, the currently available hemostasis assays only
assess isolated aspects of clot formation, which has stymied the
ﬁelds of clinical and experimental hematology given the inter-
dependence of the various components of hemostasis.
Current bleeding tests are restricted to isolated analysis of
components of coagulation (e.g., prothrombin time, activated
partial thromboplastin time), vWF, or platelet function (e.g.,
platelet function analyzer and aggregometry)4–6. Even more
“global” hemostasis assays, such as thromboelastography and
thrombin generation-based tests, fail to take into account the role
of either the endothelium or shear stress. While in vivo animal
injury models have enabled groundbreaking research in hemos-
tasis, data obtained from these non-primate models may not
directly translate to human physiology and disease7–9.
Recent advances in microfabrication technologies have pro-
vided useful, inexpensive, and easily reproducible microﬂuidic
platforms for conducting clinically relevant, microscale biological
and biochemical experiments. Accordingly, numerous research
groups, including our own, have recently applied microﬂuidic
devices to study hemostasis and thrombosis10–15. However, these
microdevices assay clot formation via perfusion of blood over
surfaces patterned with clot-activating substances—collagen,
kaolin, or tissue factor (TF)—leading to accumulation of platelet
aggregates and ﬁbrin16, and therefore function more as models of
thrombosis rather than hemostasis, where hemostasis is speciﬁ-
cally deﬁned as cessation of bleeding after vascular injury. While
Schoeman et al. recently presented an elegant microﬂuidic system
that probes bleeding time using a collagen/TF-coated micro-
channel17, it incorporates neither the limiting anticoagulant effect
of intact endothelium nor the potential procoagulant activity of
injured endothelial cells18. Therefore, a clear need exists for an
in vitro model of the hemostatic response that integrates all of the
major biological, biochemical, and biophysical components of
hemostasis in the context of vascular injury.
To that end, we have developed an in vitro vascularized
microﬂuidic mechanical injury bleeding model by integrating the
fabrication of a pneumatic microvalve and “endothelialization” of
microﬂuidics12, 13, 19–21. Our microﬂuidic uniquely comprises a
completely “endothelialized” microchannel to serve as a vascu-
lature model and a pneumatic microvalve functions as a “trap
door” to enable positive pressure to mechanically disrupt, and
therefore injure, the vascularized microchannel resulting in
“bleeding” into a separate microchannel. The anti-thrombotic
properties of the live in vitro endothelium enables the use of
human whole blood minimally anticoagulated with corn trypsin
inhibitor (CTI) to inhibit the contact pathway of clotting as blood
initially traverses the syringe/tubing before entering the micro-
ﬂuidic system. Here we demonstrate that this in vitro micro-
system enables direct, real-time visualization of the entire
hemostatic process upon mechanical vascular injury with single-
cell resolution, while allowing for tight control and modulation of
the major cellular (e.g., endothelial cell type, inclusion/exclusion
of blood cell subpopulations); biomolecular (e.g., pharmacological
agents, inhibitory antibodies); and biophysical (e.g., shear stress)
components of hemostasis. In addition, cessation of “bleeding” in
our system can be directly measured, resulting in an in vitro
analog of the bleeding time. To demonstrate the versatility of this
model, we investigate key questions within the ﬁeld of hemos-
tasis/thrombosis that have previously been technologically
infeasible to address directly. Speciﬁcally, we show that: (a) under
physiologic ﬂow conditions, the anti-platelet agent eptiﬁbatide
predominantly affects hemostatic plug formation via attenuation
of platelet aggregate density and clot contraction ; (b) inhibition
of vWF prolongs the in vitro bleeding time in a shear-dependent
manner; (c) phosphatidylserine (PSer) is expressed primarily on
the surface of endothelial cells at the site of vascular injury; and
(d) blood from hemophilia A patients features abnormal ﬁbrin
architecture and signiﬁcantly increased bleeding times. Overall,
these data establish the research-enabling and hypothesis-
generating versatility of our vascularized microﬂuidic mechan-
ical injury bleeding model for studying human blood samples and
its promise as a drug discovery platform for hemostatic and
thrombotic disorders.
Results
An in vitro mechanical injury bleeding and hemostasis model.
The polydimethylsiloxane (PDMS)-based microﬂuidic bleeding
time device (Fig. 1a) is comprised of three layers: a top “vascular”
layer that features an endothelialized microchannel (vascular
channel) that recapitulates the microvasculature, a middle valve
layer that comprises a PDMS membrane the position of which
can be pressure controlled, and a bottom valve actuator layer that
allows pressure to be introduced to the system to control valve
position (Fig. 1b). To create the endothelialized vascular channel,
the microsystem is precoated with collagen type 1 and ﬁbro-
nectin, seeded with human umbilical cord vein or aortic endo-
thelial cells, and then cultured under physiologic ﬂow conditions
until the cells reach conﬂuence—the valve is closed throughout
this process (Fig. 1c, Valve closed). To assess the hemostatic
response, vascular “injury” is introduced by providing positive
ﬂuidic pressure through and into the vascular channel and layer,
and simultaneous negative pressure in the “valve actuator” layer
to effectively pull down the valve a distance of 6 µm. This disrupts
the endothelium, creating a “bleed”with a newly formed wound
channel now continuous with the vascular channel (Fig. 1c, Valve
open, Wound created). The valve is then maintained in the open
position, with the outlet channel at ambient pressure. Immedi-
ately after injury, re-calciﬁed CTI-treated whole blood is perfused
through the device at a controlled ﬂow rate (Fig. 1c, Valve open,
Bleeding). Real-time monitoring of hemostasis can then be per-
formed via microscopy. Wound width, bleeding time (deﬁned as
the time at which red blood cells stop transiting into the wound
area), and ﬂuorescence intensity of relevant biological species are
then monitored. Importantly, in the absence of endothelial injury,
no platelet adherence, activation, or clot formation is detected
upon perfusion of the vascular channel with whole blood.
Characterization of the microﬂuidic bleeding device. To
investigate how biophysical and biochemical variables interact to
mediate the hemostatic response, we ﬁrst characterized various
aspects of bleeding and hemostasis in our “control” conditions:
conﬂuent human umbilical vein endothelial cells (HUVECs) and
re-calciﬁed blood treated with CTI, anti-CD41 to ﬂuorescently
label platelets, and ﬂuorescently labeled ﬁbrinogen. The width of
the mechanically induced wound varies between experiments as it
is a result of the valve size and the user applied pressure. Across
47 experiments, we found the mean width to be 132.49± 40.19
µm (range of minimum 73.22 to maximum 231.86 µm). To more
fully describe the ﬂuidic microenvironment, computational ﬂuid
dynamics simulations were performed, which showed that, for the
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average wound size, the initial shear stress at the middle of the
wound site is approximately 3 dyne cm−2 (range: 2–5 dyne cm−2)
and at the edge of wound approximately 7 dyne cm−2 (range: 4–8
dyne cm−2) when whole blood was perfused at 500 s−1 (Fig. 1d).
Analysis of the shear gradient demonstrates that the highest shear
occurs at the injury site (Supplementary Fig. 1). The pressure
drop along the straight section of the vascular channel was also
simulated with and without injury, yielding pressure drops on the
order of 102 Pa. We determined that the addition of the injury
negligibly reduced the pressure drop by 2.7%, which is consistent
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with hydraulic circuit analysis calculations17. As expected, upon
mechanical introduction of the wound, blood not only continues
to perfuse the vascular channel (Fig. 1c, horizontal ﬂow) but also
ﬂows into the newly formed wound channel, analogous to
“bleeding” (Fig. 1c, vertical ﬂow). As blood continues to ﬂow
through the vascular and wound channels, platelets adhere
throughout the injury site, platelet aggregation leads to the for-
mation of a hemostatic plug at the wound site, ﬁbrin poly-
merization occurs, and ﬁnally, cessation of blood ﬂow is achieved
(Fig. 1e, Supplementary Movie 1). Experimentally, median time
to cessation of blood ﬂow into the wound channel (i.e. the
“bleeding time”) for healthy donors was 503 s. We observed that
the initial wound width and bleeding time did not correlate in our
studies (Supplementary Fig. 2a, R2 = 0.088), which is likely due to
the fact that the shear stress proﬁles are all within the same order
of magnitude over the operable range of wound widths (Sup-
plementary Fig. 2b). Therefore, in our system, the time course of
hemostasis is not dependent on initial wound width or shear
stress. We posit that this is in part due to platelets immediately
adhering at the wound site and reducing the wound opening.
Interestingly, compared to venous conditions, platelet adhesion,
ﬁbrin accumulation, and bleeding time in our system were similar
under arterial cellular and shear conditions, when human aortic
endothelial cells (HAECs) were seeded in the vascular micro-
channels and blood was perfused at the average aortic shear rate
of 2500 s−1 (ﬁve times higher than that utilized in our studies
using HUVECs) (Supplementary Fig. 3). Conversely, in the
absence of endothelial cells, platelets adhered to the collagen-
coated microchannels, but hemostasis was not achieved within
the maximum recording time (1200 s, n = 3 experiments). This
suggests that the injured endothelial cells, in and of themselves,
serve a procoagulant function that is required for hemostasis
when there is no exogenous source of TF. We also visually con-
ﬁrmed the expression of P-selectin, a marker of inﬂammation, via
antibody binding, on the surfaces of platelets over the time course
of hemostasis (Supplementary Fig. 4).
Visualizing hemostasis under altered microenvironments. Our
microﬂuidic was then examined in the context of hematologically
altered conditions. A potential side effect of integrin αIIbβ3
antagonism in the prevention of arterial thrombosis is bleeding.
To investigate how this affects hemostatic plug formation, healthy
human blood was treated with 10 µg ml−1 eptiﬁbatide. There was
no signiﬁcant difference in bleeding time between eptiﬁbatide-
treated and vehicle control blood samples (Fig. 2a). Interestingly,
while there was no difference in the total area of adherent pla-
telets between the two conditions (Fig. 2b), platelet aggregation
and contraction of those aggregates, as shown via saturated pla-
telet ﬂuorescence, was more pronounced in control blood than in
eptiﬁbatide-treated blood (Fig. 2c, d and Supplementary
Movie 2). Also, by visualizing subpopulations of platelets ﬂuor-
escently labeled with a different color (calcein, in green) we
conﬁrmed clot contraction (i.e., platelets in the clots are visibly
displaced proximally and against the direction of ﬂow) in healthy
control blood, but this phenomenon was attenuated in
eptiﬁbatide-treated blood (Supplementary Movies 3 and 4).
Higher magniﬁcation visualization of the bleeding site revealed
clear co-localization of ﬁbrin(ogen) with platelets in control
conditions but not in the eptiﬁbatide-treated condition (Fig. 2e),
and this was demonstrated with Pearson correlation coefﬁcient
analysis (Fig. 2f–h). Overall, these results suggest that the integrin
αIIbβ3–ﬁbrin interaction “glues” platelets together at the site of
vascular injury, but that this interaction alone is not necessary for
hemostasis in the microvasculature.
vWF is a shear-responsive protein essential for platelet
adhesion in conditions of arterial ﬂow22. Moreover, the interac-
tion of factor VIII with vWF allows the persistence of circulating
factor VIII within the vasculature. vWF co-localized wth
endothelial cells at the wound site and in platelets in the
hemostatic plug (Fig. 3a). The AVW3 antibody blocks the
interaction of vWF with its cognate platelet receptor GPIb-IX
without affecting the interaction of vWF with factor VIII. Using
AVW3, we quantitatively assessed how inhibition of the
GPIb–vWF interaction speciﬁcally affects hemostatic plug
formation. The hemostatic response using AVW3-treated whole
blood was assessed at venous (500 s−1) and arteriolar (2500 s−1)
shear rates. Strikingly, yet consistent with the known shear-
responsive nature of vWF, vWF inhibition almost exclusively
prevented hemostasis in conditions of arteriolar ﬂow. At a shear
rate of 500 s−1, the median bleeding time in the presence of
AVW3 was 559.5 s, which was not statistically different compared
to that of control conditions, while at 2500 s−1, hemostasis was
not achieved over the experimental time scales in the presence of
AVW3 (Fig. 3b), indicating that a speciﬁc deﬁciency of vWF
activity primarily impacts hemostasis at high shear.
PSer is an integral component of the nascent hemostatic plug,
as its exposure on cell surfaces provides an essential surface for
the assembly of coagulation enzyme complexes and the
ampliﬁcation of the coagulation cascade23. The timing and
localization of PSer exposure was examined using ﬂuorescently
labeled annexin V (Fig. 4). Importantly, conﬂuent endothelial
cells did not display PSer prior to injury (Fig. 4, left top). Blood
was perfused at 500 s−1 (Supplementary Movies 5 and 6), and
immediately upon wound initiation, PSer was detected on
endothelial cells, but only in the vicinity of the wound area.
The amount of PSer exposure on the injured endothelial cells
increased over time, while the plasma membrane stain decreased;
this trend continued locally even after hemostasis was achieved.
Injured cells were readily discerned even at the initial time of
wounding by the disruption of previously conﬂuent cell-cell
contacts. PSer-positive (i.e., PSer is exposed on the surface of
platelet) events could be observed both at the sites of denuded
endothelium adjacent to the intact endothelium and within the
hemostatic plug. However, the majority of these platelets were
Fig. 1 An “endothelialized” microﬂuidic system coupled with a microengineered pneumatic valve that induces a vascular “injury” functions as a
comprehensive in vitro mechanical injury bleeding model. a Our microﬂuidic-based bleeding device is constructed from b three polydimethylsiloxane
layers: a vascular layer comprised of a vascular channel and outlet channel, a valve layer, and a valve actuator layer. c First, endothelial cells are cultured to
conﬂuence in the vascular channel while the pneumatic valve is in the closed position (left). When the valve layer is pulled down by negative pressure in
valve actuator channel (pull) and mechanical ﬂuidic pressure (push) is applied through outlet channel, the vascular channel is disrupted and endothelial
injury is mechanically induced (middle). Blood is perfused while the valve is maintained in the open position and ﬂows through the vascular channel
(horizontal) as well as the newly created “bleeding” wound channel, which leads to the outlet channel (right). d A computational ﬂuid dynamic COMSOL
simulation shows initial wall shear stresses when the mechanical injury is introduced. e Our in vitro microcvasculature mechanical injury model enables
real-time visualization of the entire hemostatic process. Conﬂuent endothelial cells (stained via a plasma membrane stain—blue) are disrupted when the
valve opens and “bleeding” occurs through the injury site. Immediately, platelets (stained via CD41—red) begin to adhere at the injury site (red arrow)
followed by ﬁbrinogen/ﬁbrin accumulation (ﬂuorescent tagged ﬁbrinogen, green) until ﬁnally hemostasis is achieved. All scale bars= 50 µm
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PSer negative (i.e., PSer was bound to the inner leaﬂet of the
platelet membrane and not exposed to the surface, and therefore
not detected with the annexin V stain). Also when we used ﬁbrin-
speciﬁc antibody 59D824, we observed signiﬁcant amounts of
ﬁbrin accumulation at the damaged edges and detached portions
of the endothelial cell membranes (Supplementary Fig. 5). This
suggests that PSer expressed on injured endothelial cells serves as
the principal prothrombotic surface for initial hemostasis, while
platelet PSer does not appear to play a signiﬁcant role initially.
These studies highlight our system’s capabilities for controlled
visual analysis of the many interconnected facets of hemostasis,
and provides spatiotemporal insight into these phenomena.
TF, a ligand for factor VIIa that leads to thrombin production
and clot formation, is an integral component in the initiation of the
coagulation cascade both in vivo and in vitro17. In vivo, TF is
contained within the subendothelium and smooth muscle cells,
with another potential circulating source in white blood cells,
which can be observed within the hemostatic plug (Supplementary
Fig. 6a and Supplementary Movie 7). To investigate whether TF
stemming from leukocytes or other cell sources was required for
hemostasis in our system, we used whole blood with an anti-TF
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Fig. 2 Integrin αIIbβ3 antagonism alters hemostatic plug architecture by inhibiting platelet–ﬁbrin binding and clot contraction. a Healthy blood treated with
10 µg ml−1 eptiﬁbatide, an anti-platelet drug commonly used in the clinical setting, and healthy blood with vehicle control exhibit similar in vitro bleeding
times. b Moreover, the total areas of adhered platelets are also similar between the two conditions. c However, when comparing platelet aggregation
followed by clot contraction, which is tracked by measuring the areas of saturated intensity of ﬂuorescently labeled platelets over time, eptiﬁbatide-treated
blood exhibited signiﬁcantly less platelet aggregation and clot contraction over the time course of hemostasis as compared to vehicle control conditions.
The error bars in the graphs show standard errors (control n= 3, eptiﬁbatide n= 4). Double asterisk (**) shows P-value< 0.05 by Student's t-test. d Heat
map of adhered platelets shows dense platelet aggregates with saturated ﬂuorescence intensity formed in vehicle control conditions at 20min after
bleeding (top) while no aggregation or clot contraction observed in eptiﬁbatide-treated blood (bottom). e Under the eptiﬁbatide-treated conditions,
platelet–ﬁbrin binding (as deﬁned by co-localization of platelets—red—and ﬁbrinogen/ﬁbrin—green) was markedly decreased compared to that of the
control conditions. f, g The analyzed images of a representative experiment with healthy control and eptiﬁbatide-treated blood samples (left) and the
corresponding platelet-ﬁbrin(ogen) co-localization plot (right). Each co-localization plot displays the pixel intensity of the red channel (x axis),
corresponding to platelets, plotted against the pixel intensity of the green channel (y axis), corresponding to ﬁbrin(ogen), of each pixel in the respective
image. The red lines show the Pearson correlation coefﬁcient lines. h Comparing Pearson correlation coefﬁcients between healthy control and eptiﬁbatide-
treated samples (n= 5 for each condition) reveals that co-localization is more pronounced in the control condition (Student's t-test, P= 0.008). All scale
bars= 50 µm. Bars in graph represent median values
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antibody (TF9-10H10). There was no difference in bleeding time in
TF-inhibited samples as compared to controls (n = 2). This
suggests that injured endothelial cells and exposed collagen are
sufﬁcient to elicit a clotting response in the context of whole blood
and physiologic shear stress. To assess the effect of exogenous TF
in our system, vascular microchannels were precoated with 1 nM
of TF and collagen prior to the seeding endothelial cells. We
observed enhanced ﬁbrin(ogen) accumulation at early time points
(Supplementary Fig. 6b and c). These preliminary results highlight
the utility of our system in assessing the synergistic relationship
between coagulation factors in the hemostatic process.
To demonstrate the clinical relevance of the in vitro bleeding
time in our microﬂuidic in the context of coagulation disorders,
healthy blood was treated with an antibody against the A2
domain of Factor VIII (anti-A2 mAb 2–76) to induce a severe
hemophilia A phenotype. In the absence of functional factor VIII,
ﬁbrin accumulation was minimal over the experimental time
course. While platelet accumulation was unaffected (Fig. 5a),
signiﬁcant reduction of ﬁbrinogen/ﬁbrin was observed at later
time points (Fig. 5b, at 10 and 15min), and this absence of
coagulation resulted in an unstable clot with repeated re-bleeding
(Fig. 5c and Supplementary Movie 8). In fact, hemostasis was not
achieved in any of the antibody-induced hemophilia samples
(Fig. 5d, n = 8). Furthermore, we obtained clinical blood samples
from severe Hemophilia A patients and found that hemostasis
was not achieved in our microﬂuidic bleeding model for any of
the patient hemophilia samples (Fig. 5e, n = 4, Supplementary
Movie 9). As expected, we again saw a clear reduction in
ﬁbrinogen/ﬁbrin accumulation (Fig. 5f).
Taken together, these studies highlight how our microsystem
provides spatiotemporal insight into the cellular and molecular
interactions of hemostasis. Furthermore, by introducing clinical
patient samples, our bleeding device allows us to study hemostasis
in different disease states.
Discussion
Here we describe the development and characterization of what,
to our knowledge, is the ﬁrst reported microﬂuidic-based in vitro
bleeding model that recapitulates key aspects of in vivo
mechanical injury of the microvasculature. The microsystem
uniquely incorporates the major aspects of hemostasis, including
platelets (and all other blood cell types and subpopulations),
coagulation factors, an intact and functional endothelium, and
shear stress, all of which can be tightly controlled, included/
excluded, and varied. When used in conjunction with ﬂuores-
cently labeled antibodies or cellular dyes, the entire hemostatic
process can be measured and quantitatively evaluated in real time
with single-cell resolution via microscopy.
The use of microﬂuidic platforms to study clot formation
under physiologic ﬂow conditions is well established, and their
utility in differentiating limited aspects of the hemostatic process
in both normal and pathophysiologic states has been elegantly
demonstrated17. However, the presented system uniquely reca-
pitulates important in vivo aspects of hemostasis after vascular
injury not found in other microﬂuidic systems. First, blood vessel
injury with blood loss due to mechanical trauma is accurately
modeled by the endothelialized microchannel coupled with a
microengineered pneumatic valve. This enables the visualization
and quantitative assessment of hemostatic plug formation and
time to cessation of “bleeding”. In addition, the inclusion of the
endothelium, with its antithrombotic properties, enables the use
of only minimal anticoagulation with CTI, and therefore the
inclusion of whole blood. This, in turn, uniquely allows for
assessment of endothelial interactions with all blood cell sub-
populations at the site of vascular injury under physiologic, or
near physiologic, conditions. Moreover, we ﬁnd that the injured
endothelium, in concert with exposed collagen, is sufﬁcient to
cause hemostasis in the absence of TF.
Our microsystem allows us to make unique quantitative spa-
tiotemporal insights into how, under conditions of ﬂow and in
the context of an intact and functional endothelium, components
of clot formation function both physiologically and in pathologic
states to initially re-establish vascular integrity. Eptiﬁbatide,
despite its clinically problematic effects on hemostasis, had no
effect on in vivo bleeding time in both preclinical animal and
clinical human trials25, 26. Consistent with these studies, we
demonstrate that eptiﬁbatide does not effect in vitro bleeding
time. But here, through direct visualization of the hemostatic
process, we identify that inhibition of the ﬁbrin(ogen)–αIIbβ3
interaction dramatically alters the cellular architecture of human
hemostatic plug formation. Speciﬁcally, in our system, while
eptiﬁbatide does not affect the number of platelets adhered to the
collagen matrix, it leads to decreased clot contraction and
therefore a lower density of platelets within the hemostatic plug
(Fig. 2 and Supplementary Movies 2–4). As clot contraction is
dependent on ﬂow conditions27, these data showcase the
experimental versatility of our system, in this case in providing
new physiologic insight into the effects of a well-established
pharmacologic agent.
While vWF is known to be a shear-responsive protein28, this
effect has not been apparent in murine models of venous and
arterial thrombosis. Here the capability to tightly control the
hemodynamic environment in the context of vascular injury
demonstrates that bleeding time is vWF dependent at high but
not low shear conditions (Fig. 3) through the limitation of platelet
accumulation, and that this effect can be separated from vWF’s
role as a carrier of factor VIII. On the other hand, severe deﬁ-
ciency of factor VIII activity severely limited hemostasis by pre-
venting ﬁbrin formation and the formation of a stable hemostatic
plug. Together, these results demonstrate the ability of our
microﬂuidic to differentiate the precise physiologic mechanism by
which a hemorrhagic diathesis might occur.
Finally, this microsystem affords a reductionist approach that
allows for the resolution of longstanding questions that have been
B
le
ed
in
g 
tim
e 
(s
)
**
>1200
1000
500
 s-1
 (co
ntro
l)
500
 s-1
 + A
VW
3
250
0 s
-1
250
0 s
-1 +
 AV
W3
750
500
250
0
a b
Fig. 3 Functional inhibition of vWF causes prolonged bleeding in high shear
conditions. a vWF (green) co-localizes with injured endothelial cells as well
as with platelets. Endothelial cells are stained with plasma membrane stain
(blue) while platelets are stained with anti-CD41 (red). b When healthy
blood was treated with the AVW3 antibody, which binds and inhibits the A1
domain of vWF, we observed prolonged bleeding time only at arteriolar
(2500 s−1) shear rates comparted to venular shear rates (500 s−1). One-
way ANOVA indicate statistically signiﬁcant difference among these four
conditions, and Dunn’s multiple comparison test further show that bleeding
times are signiﬁcantly different between the 500 s−1 control and 2500 s−1
with AVW3 conditions (**). Scale bar= 50 µm. Bars in graph represent
median values
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-02990-x
6 NATURE COMMUNICATIONS |  (2018) 9:509 |DOI: 10.1038/s41467-018-02990-x |www.nature.com/naturecommunications
a b
Before injury After injury 3 min
6 min 11 min 21 min
After 30 min
Fig. 4 Annexin V binding reveals rapid exposure of phosphatidylserine (PSer) on endothelial cell surfaces but not on platelets. a Conﬂuent endothelial cells
before injury show no PSer exposure on their surfaces (top left). Immediately after mechanical injury is induced, the endothelial cells in the strict vicinity of
the wound exhibit PSer exposure, as measured with annexin V binding (red) in a time-dependent manner while losing their plasma membrane staining over
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and hemostasis was achieved, the majority of the platelet aggregates did not exhibit signiﬁcant amounts of PSer exposure, in contrast with endothelial cells
at the wound site, which exhibit signiﬁcant PSer exposure. All scale bars= 50 µm
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difﬁcult to assess in vivo. For example, it has been debated
whether the PSer exposure that contributes to ﬁbrin formation at
the site of vascular injury occurs ﬁrst on the endothelial surface or
the platelet surface. In our system, we clearly demonstrate that
PSer is exposed on injured endothelial cells within seconds of a
mechanical vascular injury and expression continues to increase
in the direct vicinity of the injury over the time course of
hemostasis, while platelet PSer expression at the wound site
occurs later. While PSer exposure on endothelial cells has been
reported as being more signiﬁcant than platelet PSer, the timing
of these different events has been unresolved and debated18, 29–34.
This highlights the research-enabling aspect of our technology to
generate new hypotheses.
No in vitro device can fully recapitulate all in vivo conditions,
and our system is not without limitations. Owing to its small
scale, our microsystem physically models the microvasculature
rather than larger vessels that are dictated by different ﬂuid and
mass transport phenomena due to the larger characteristic lengths
and ﬂow rates observed in larger vessels. The microscale
dimensions of our system result in steady,laminar ﬂow, which
enables shear stress to be tightly controlled and modulated to
mimic venular/small venous to arteriolar/small arterial condi-
tions, thereby enabling the dynamic physiologic range of the
microcirculation7. We observe that the bleeding time remains
unchanged under arterial and venous shear conditions with
HAECs and HUVECs. We conjecture that under these different
conditions, our system, in which there is a mechanical injury of
relatively constant size that is induced at a speciﬁc site of an
endothelialized channel, two opposing phenomenon are occur-
ring. On the one hand, the increased pressure and velocity under
arterial conditions should lead to more “bleeding” in our system.
On the other hand, the increased ﬂux of hemostatic components
including platelets and coagulation factors should lead to a more
rapid formation of a hemostatic plug, especially given the fact that
the injury size is unchanged. This then diverts blood ﬂow back to
the vascular channel and additional platelet/ﬁbrin accumulation
ceases, which is what occurs physiologically. In addition, the
endothelial cells themselves, which are from venous and arterial
vascular beds, may also be biologically more “tuned” to their
corresponding shear conditions. These phenomenon therefore
likely collectively cancel each other out leading to similar
hemostatic plug formation and bleeding times under arterial and
venous conditions. A smooth muscle layer is not incorporated
into our system and therefore our in vitro bleeding model
includes neither smooth muscle vasoconstriction nor the effects
of subendothelial tissue damage, such as smooth muscle cell-
derived TF, which may, in turn, underestimate the role of ﬁbrin.
Although we collected data with TF-coated vascularized channels,
TF on the microchannel surface may not biologically function as
identically as TF from smooth muscle cells. Despite these lim-
itations, because our model more accurately recapitulates the
microvasculature where smooth muscle cells are less prevalent,
especially on the venular and venous side, and TF may have less
of a role7, our data are likely not signiﬁcantly affected. Indeed, we
believe that this system is best leveraged as a complementary
technology when used in conjunction with in vivo bleeding
models as the limitations of one system can be addressed by the
other. For example, murine bleeding models such as the cre-
master laser injury model obviously involve all physiologic
aspects of hemostasis35, 36. However, these experiments are
relatively costly and involve signiﬁcant amounts of labor while the
mechanism of injury may not be physiologic, which may con-
found the data collected and possibly lead to artefact. The vas-
cularized microﬂuidic bleeding model presented here
recapitulates a true mechanical injury and enables the use of
human (and therefore patient) blood samples, while the
experiments themselves are relatively inexpensive and simple to
conduct.
With the capability to integrate an intact endothelium, phy-
siologic ﬂow conditions, a controlled mechanical injury, and
human whole blood in a controlled manner, our vascularized
microﬂuidic bleeding model is ideal for studying the global
hemostatic potential of patient samples in a microvascular model
and for dissecting pathophysiologic mechanisms of disease. In
addition, with the capability to holistically assess and visualize the
entire hemostatic process, this system can immediately aid the
ﬁelds of experimental hematology and vascular biology as a novel
research enabling tool. Moreover, these attributes also enable the
system to potentially function as an entirely new category of
diagnostic for bleeding disorders, although the standardization
and characterization of the in vitro endothelium is needed and
will be the basis of upcoming studies. Finally, this endothelialized
microﬂuidic-based in vitro bleeding model also holds signiﬁcant
promise as a drug discovery platform, potential diagnostic, and
therapy-guiding tool for hemostatic and thrombotic disorders.
Methods
Sample collection. Human blood was collected according to our institutes’
Institutional Review Board-approved protocols per the Declaration of Helsinki and
conditioned for each experiment using the dyes, antibodies, and drugs as described
as below in Methods and also in Results sections.
Reagents and antibodies. Plasma membrane stain (CellMask Deep Red, C10046),
ﬂuorescent-tagged ﬁbrinogen (F13191), annexin V (A13202), ﬂuorescently tagged
secondary antibodies against mouse IgG (A11001, A11004, 1:400), and calcein
(C34852, 2 µg ml−1) were purchased from Life Technologies. Eptiﬁbatide (Integ-
rilin) was purchased from COR Therapeutics. Antibodies were purchased from
Fisher Scientiﬁc (CD41, NB100-2614, 1:400), Santa Cruz Biotechnology (P-selectin,
sc-19996, 1 µg ml−1), Bio-Rad (vWF-FITC, AHP062F, 1:1000), BD (CD45, 555483,
1:400), and abcam (TF, ab35807, 1:200). Antibody AVW-3 and 59D8 (Alexa Fluor
488 conjugated) were provided by Dr. Shawn M. Jobe (Blood Center of Wisconsin,
10 µg ml−1, 1:100) and mAb 2–76 by Dr. Shannon L. Meeks (Emory University, 10
µg ml−1)37, 38.
Microﬂuidic device construction. The microﬂuidic devices used in this study were
fabricated using soft lithography with PDMS (Ellsworth Adhesive) in three separate
layers: vascular layer, valve layer, and valve actuator. The vascular layer (with
vascular channel 150 µm width and 50 µm height) was oxygen plasma bonded
using a plasma cleaner (Harrick Plasma, PDC-32G) to the valve layer (50 µm
thick), which contained a partially shielded area to prevent oxygen plasma treat-
ment and, in turn, to create the movable pneumatic valve (Supplementary Fig. 7).
Inlet and outlet holes were then punched into the bonded layers and oxygen
plasma bonded to the valve actuator (with valve channel, 6 µm in height).
Endothelialization of the microﬂuidic device. All the microchannels (vascular,
outlet, and valve) of pre-vacuumed devices were infused with collagen type 1 (BD,
1 mgml−1), and then only the vascular channel was infused with ﬁbronectin
(Sigma-Aldrich, 50 µg ml−1) before HUVECs or HAECs (Lonza) were seeded at a
concentration of 10 million cells ml−1 in 8% Dextran (Sigma-Aldrich) in their
growth media (EGM-2, Lonza). Fifteen minutes after cell adhesion, the device was
washed with fresh media and further incubated at 37 °C for 2 h before the syringe
ﬁlled with cell growth media was connected and media was perfused into the
vascular channel using a syringe pump (PhD Ultra, Harvard Apparatus) at shear
rates of 500 or 2500 s−1 until cells grew to conﬂuence.
Mechanical induction of vascular injury and bleeding assay. Vascular injury
was introduced by making an opening between vascular layer and valve layer,
which were not covalently bonded together, by inducing positive hydraulic pressure
with a syringe, while pulling the valve layer downward using a separate syringe
pump. Outlet tubing in the outlet channel was then cut at the base of the device to
achieve ambient pressure. Whole blood collected in sodium citrate buffer (BD) and
treated with CTI (40 µg ml−1, Haematologic Technologies) was conditioned and re-
calciﬁed before the experiments and perfused into the channel using a syringe
pump at shear rates of 500 or 2500 s−1. Time lapse images were collected
approximately one image every 10 s (6 frames per minute) by a confocal micro-
scope (LSM 700, Zeiss) during the experiments and bleeding time was measured.
Data analysis. Statistical analysis (Mann–Whitney test and one-way analysis of
variance) of bleeding time was performed and graphed with Graphpad Prism 5.
Fluorescence intensity, co-localization (Pearson correlation coefﬁcient), and area
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were measured by Image J (NIH) and Zen (Zeiss) and statistically analyzed by
Student's t-test. P-value < 0.05 was considered as signiﬁcant. COMSOL was used
for computational ﬂuid dynamics simulations. The intensity map of ﬂuorescent
signals was created with MATLAB (MathWorks).
Data availability. The datasets generated and/or analyzed during the current study
are available from the corresponding author on reasonable request.
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